WVE
Wave Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$4.35
−2.03%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.47
From 52W high−79.59%
Volume4.24M
Market cap$857.16M
P/E (TTM)—
P/S (TTM)13.1x
Div yield—
Key dataSep 18, 2026
Open
$4.47
From 52W high
−79.59%
Volume
4.24M
Market cap
$857.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
29.6
MomentumView details →
1D Return
−2.03%
YTD Return
−74.53%
SummaryUpdated Jun 1, 2026
Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage genetic medicine company founded in 2012 and based in Singapore. The company specializes in developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. Wave went public in November 2015 and has since established itself as a pioneer in the field of RNA-targeted therapeutics, with a particular focus on rare genetic diseases and common conditions like obesity. The company has built strategic partnerships with major pharmaceutical companies including Pfizer, Takeda, and GlaxoSmithKline to advance its innovative therapeutic approaches.
Similar companies
Latest newsMore news →
Wave Life Sciences completed its redomiciliation from a Singapore company to a Delaware corporation via a scheme of arrangement under Singapore law.41d agoWave Life Sciences Ltd. reported financial results for the second quarter of 2026, with total revenue of $2.3 million and a net loss of $69.4 million.53d ago